8-azahypoxanthine: an antimalarial that inhibits hypoxanthine-guanine-xanthine phosphoribosyltransferase; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
8-azahypoxanthine : A triazolopyrimidine that consists of 1,4-dihydro-7H-[1,2,3]triazolo[4,5-d]pyrimidine bearing an oxo substituent at position 7. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 135410720 |
| CHEMBL ID | 219416 |
| CHEBI ID | 136532 |
| SCHEMBL ID | 1230976 |
| SCHEMBL ID | 14094281 |
| MeSH ID | M0040166 |
| Synonym |
|---|
| ae 200 |
| 1h-1,3-triazolo[4,5-d]pyrimidin-7-ol |
| 7-hydroxy-v-triazolo[d]pyrimidine |
| 7h-v-triazolo[4, 1,6-dihydro- |
| 7-hydroxy-1,3,4,6-pentaazaindene |
| v-triazolo[4,5-d]pyrimidin-7-ol |
| 7h-1,3-triazolo[4,5-d]pyrimidin-7-one, 1,4-dihydro- |
| 1h-v-triazolo[4,5-d]pyrimidin-7-ol |
| 7h-1,2,3-triazolo[4,5-d]pyrimidin-7-one, 1,4-dihydro- |
| NCI60_001853 |
| 3,6-dihydro-[1,2,3]triazolo[4,5-d]pyrimidin-7-one |
| 8-azahypoxanthine |
| 3,6-dihydrotriazolo[4,5-d]pyrimidin-7-one |
| 2683-90-1 |
| 1,4-dihydro-7h-[1,2,3]triazolo[4,5-d]pyrimidin-7-one |
| azahypoxanthine |
| CHEBI:136532 |
| 1h-1,2,3-triazolo(4,5-d)pyrimidin-7-ol |
| 8-azahx |
| 7-hydroxy-1,2,3,4,6-pentaazaindene |
| A0555 |
| CHEMBL219416 |
| 2,3-dihydrotriazolo[4,5-d]pyrimidin-7-one |
| 3h-[1,2,3]triazolo[4,5-d]pyrimidin-7-ol |
| 3,6-dihydro-7h-[1,2,3]triazolo[4,5-d]pyrimidin-7-one |
| F2124-0964 |
| F2147-0425 |
| AKOS003272028 |
| NCGC00188261-01 |
| AKOS005206808 |
| ai3-50259 |
| 7h-1,2,3-triazolo(4,5-d)pyrimidin-7-one, 3,6-dihydro- |
| 7h-v-triazolo(4,5-d)pyrimidin-7-one, 1,6-dihydro- |
| einecs 220-244-3 |
| 1h-v-triazolo(4,5-d)pyrimidin-7-ol |
| 7-hydroxy-v-triazolo(d)pyrimidine |
| nsc 22709 |
| 7h-1,2,3-triazolo(4,5-d)pyrimidin-7-one, 1,4-dihydro- |
| v-triazolo(4,5-d)pyrimidin-7-ol |
| GEO-00241 |
| FT-0621502 |
| 7h-1,2,3-triazolo[4,5-d]pyrimidin-7-one,3,6-dihydro- |
| AKOS015854536 |
| 7-hydroxy-3h-[1,2,3]triazolo[4,5-d]pyrimidine |
| 2,2-dibromodiphenylacetylene |
| DTXSID1062590 |
| SCHEMBL1230976 |
| mfcd08692088 |
| SY019936 |
| TS-00032 |
| 1,4-dihydro-7h-[1,2,3]triazolo[4,5-d]pyrimidin-7-one # |
| W-200265 |
| 1h-[1,2,3]triazolo[4,5-d]pyrimidin-7(4h)-one |
| SCHEMBL14094281 |
| CS-0081731 |
| 3h-[1,2,3]triazolo[4,5-d]pyrimidin-7(6h)-one |
| AKOS028109374 |
| mfcd00005804 |
| 7-hydroxy-1,2,3-triazolo[4,5-d]pyrimidine |
| 7-hydroxy-3h-1,2,3-triazolo[4,5-d]pyrimidine |
| 2,6-dihydrotriazolo[4,5-d]pyrimidin-7-one |
| 1h-[1,2,3]triazolo[4,5-d]pyrimidin-7(6h)-one |
| T70692 |
| AKOS037491874 |
| A877122 |
| 3h,6h,7h-[1,2,3]triazolo[4,5-d]pyrimidin-7-one |
| EN300-235705 |
| Role | Description |
|---|---|
| antimalarial | A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human. |
| EC 2.4.2.8 (hypoxanthine phosphoribosyltransferase) inhibitor | An EC 2.4.2.* (pentosyltransferase) inhibitor that interferes with the action of hypoxanthine phosphoribosyltransferase (EC 2.4.2.8). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| nucleobase analogue | A molecule that can substitute for a normal nucleobase in nucleic acids. |
| triazolopyrimidines | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 14.1254 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
| DNA dC->dU-editing enzyme APOBEC-3G isoform 1 | Homo sapiens (human) | Potency | 8.4882 | 0.0580 | 10.6949 | 26.6086 | AID602310; AID651813 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 6.3167 | 0.0259 | 11.2398 | 31.6228 | AID651814; AID651815 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (57.14) | 18.7374 |
| 1990's | 2 (28.57) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||